Core Viewpoint - The company is holding its first extraordinary general meeting of shareholders in 2025 to discuss several key proposals, including the cancellation of the supervisory board, cash management using idle funds, and the election of a new board of directors [1][7][9]. Group 1: Meeting Proposals - Proposal 1 involves the cancellation of the supervisory board and amendments to the company's articles of association, with the supervisory board's powers being transferred to the audit committee of the board of directors [7][8]. - Proposal 2 seeks approval to use up to RMB 4 billion of temporarily idle funds for cash management, focusing on safe and liquid investment products [8][9]. - Proposal 3 is for the election of three non-independent directors to the third board of directors, with candidates nominated for the positions [9][10]. - Proposal 4 involves the election of three independent directors to the third board of directors, with candidates also nominated for these positions [11][12]. Group 2: Meeting Procedures - The meeting will be conducted with both on-site and online voting, with specific time slots for voting outlined [4][5]. - Shareholders must register and provide identification to participate, and only registered attendees can vote on-site [2][3]. - The meeting will follow a structured agenda, including the introduction of attendees, discussion of proposals, and voting [6][8].

杭州安旭生物科技股份有限公司 2025 年第一次临时股东大会会议资料 杭 州 安 旭 生 物 科 技 股 份 有 限 公 司 2025 年第一次临时股东大会会议资料 股票简称：安旭生物 股票代码：688075 2025 年 8 月 22 日 1 杭州安旭生物科技股份有限公司 2025 年第一次临时股东大会会议资料 目 录 | 2025 年第一次临时股东大会须知………………………………………………………..………3 | | --- | | 年第一次临时股东大会议程…………………………………………………………..… 5 2025 | | 议案一：关于取消监事会、修订<公司章程>并办理工商变更登记及修订相关制度的议案…7 | | 议案二：关于使用部分暂时闲置自有资金进行现金管理的议案………………………….…..8 | | 议案三：关于董事会换届选举暨选举第三届董事会非独立董事的议案………………………9 | | 议案四：关于董事会换届选举暨选举第三届董事会独立董事的议案………………….….…10 | 2 杭州安旭生物科技股份有限公司 2025 年第一次临时股东大会会议资料 2025 年第一次临时股东大会须知 为了维护 ...

Group 1 - The core viewpoint is that the A-share market is stabilizing, and growth stocks are expected to rebound, with a focus on sectors less affected by external factors and more aligned with internal growth, particularly in the large financial sector [1][4]. Group 2 - The electronic industry is the most favored by brokerages, covering 127 stocks, followed closely by the pharmaceutical and mechanical equipment industries, with 125 and 124 stocks respectively [2]. - Brokerages have conducted research on 1,061 stocks this year, significantly higher than the 740 stocks researched in the same period last year [2]. - The top three brokerages in terms of research frequency are CITIC Securities, CICC, and CITIC Jiantou, with 386, 373, and 323 research instances respectively [3]. Group 3 - Brokerages are optimistic about the A-share market's future, with expectations of a recovery driven by strong performance in growth stocks, particularly in sectors like photovoltaics, wind power, smart driving, and digital economy [4]. - There are indications of multiple bottom signals in the A-share market, suggesting a potential new upward cycle as external negative factors ease [4]. - The valuation of A-shares is nearing historical lows, indicating that market rebounds are likely to continue, with a focus on previously oversold stocks and growth sectors like new energy and semiconductors [4].

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Anxu Biological, which closed at 42.93 yuan with a PE ratio of 34.94 times, below the industry average of 56.56 times [1][2] - Anxu Biological's total market capitalization is 5.456 billion yuan, ranking 68th in the medical device industry based on PE ratio [1][2] - The company specializes in the research, production, and sales of POCT reagents and instruments, and has received multiple certifications including EU CE, Canadian, and Australian certifications [1] Group 2 - As of March 31, 2025, Anxu Biological had 5,935 shareholders, a decrease of 278 from the previous period, with an average holding value of 352,800 yuan per shareholder [1] - The latest quarterly report for Q1 2025 shows a revenue of 115 million yuan, a year-on-year decrease of 10.90%, and a net profit of 34.03 million yuan, down 51.52% year-on-year, with a gross margin of 42.32% [1]

Group 1 - The company is revising its articles of association, which requires approval from the shareholders' meeting and authorization for related registration procedures [1][2] - The revised governance systems have been approved by the company's board and supervisory board, with some requiring further approval from the shareholders' meeting [2][3] Group 2 - The company held an employee representative meeting on August 6, 2025, to elect Dong Wenkun as the employee representative director for the third board, whose term aligns with the new board [3][4] - Dong Wenkun has a background in pharmaceutical engineering and has held various positions within the company, including director of research and development [4][5] - As of the announcement date, Dong Wenkun does not directly hold company shares but has indirect holdings through a partnership, and he meets all legal qualifications for the position [5]

Group 1 - The company is undergoing a board re-election process as the term of the second board is about to expire, with the third board candidates being nominated [1][2][3] - The candidates for the third board include three non-independent directors and three independent directors, with the independent candidates requiring approval from the Shanghai Stock Exchange before being submitted to the shareholders' meeting [2][3] - The new board members will serve a term of three years starting from the date of approval by the shareholders' meeting [2][3] Group 2 - The second board members have been diligent and contributed positively to the company's operations during their tenure [3] - The company will continue to operate under the current board until the new board is approved by the shareholders [3] Group 3 - The company plans to use up to RMB 4 billion of temporarily idle funds for cash management, focusing on safe and liquid investment products [21][25] - The cash management aims to improve fund utilization efficiency and increase returns while ensuring the company's normal operations and fund safety [23][31] - The board and supervisory committee have approved this cash management plan, which will be submitted for shareholder approval [32][33] Group 4 - The company is proposing to cancel its supervisory board and transfer its responsibilities to the audit committee of the board, in line with recent regulatory changes [78][79] - The company will revise its articles of association to reflect these changes, including the removal of references to the supervisory board [78][81]

风险提示：股市有风险，投资需谨慎。 8月6日晚间，安旭生物发布多份公告。公司第二届董事会第十八次会议审议通过了董事会换届选举等多 项议案。同时，公司将于8月22日召开2025年第一次临时股东大会，审议取消监事会等议案。此外，公 司拟使用不超过40亿元闲置自有资金进行现金管理，该议案尚需股东大会审议通过。 资金流向方面，8月6日安旭生物主力资金净流出379.91万元，近五个交易日累计净流出126.40万元。 安旭生物8月6日报收42.29元，较前一交易日下跌0.37元，跌幅0.87%。当日成交量为12289手，成交金 额达0.53亿元。该股开盘报42.66元，盘中最高触及43.99元，最低下探42.10元，振幅4.43%。 安旭生物属于医疗器械行业，专注于体外诊断产品的研发、生产和销售。公司产品涵盖传染病检测、毒 品检测、妊娠检测等多个领域，业务范围涉及全球多个国家和地区。 ...

（文章来源：证券日报） 证券日报网讯 8月6日晚间，安旭生物发布公告称，公司第二届监事会第十六次会议审议通过了《关于 取消监事会、修订并办理工商变更登记及修订相关制度的议案》等多项议案。 ...

（文章来源：证券日报） 证券日报网讯 8月6日晚间，安旭生物发布公告称，公司第二届董事会第十八次会议审议通过了《关于 董事会换届选举暨提名第三届董事会非独立董事候选人的议案》等多项议案。 ...

Group 1 - The company announced the organization of a staff representative meeting on August 6, 2025, to elect Mr. Dong Wenkun as the employee representative director of the third board of directors [2] - Mr. Dong Wenkun's term will be consistent with that of the company's third board of directors [2]